DFTX Definium Therapeutics, Inc.
$37.96▼ -0.37%
Healthcare
Other
After hours
$37.40▼ -1.48%
Oct 29, 7:17 PM ET
Volume 1.40M
Avg Volume (10D) 1.79M
Key Metrics & Fundamentals
Market Cap
$5.10B
P/E Ratio
–
Div Yield
0.00%
52W Range
10.47 - 49.70
% vs 50 MA
0.03%
% vs 200 MA
28.69%
RSI-14
56.5
MACD Histogram
+0.5800
Beta (1Y vs SPY)
1.01
Free Cash Flow
-$52.78M
Gross Rev
$0
Gross Profit
$0
EBITDA
-$71.49M
COGS
–
Operating Exp
$75.08M
Operating Income
-$75.08M
EBIT
-$75.08M
Pretax Income
-$158.99M
Net Income
-$158.99M
EPS (Diluted)
-1.44
Price & Volume History
Loading chart…
Recent News
Definium Therapeutics to Report Third Quarter 2026 Financial Results on November 9, 2026
Business Wire · Oct 29, 2026 4:01 PM ET
Definium Therapeutics Announces New Employee Inducement Grants
Business Wire · Oct 26, 2026 4:01 PM ET
Definium Therapeutics (DFTX) Stock May Trade Above Fair Value On Book Value
Simply Wall St. · Oct 19, 2026 6:15 PM ET
Definium Therapeutics Investors Remain Concerned Over Psychedelics' Commercial Scalability, RBC Says
MT Newswires · Oct 19, 2026 11:52 AM ET
Definium Therapeutics Announces New Employee Inducement Grants
Business Wire · Oct 13, 2026 4:01 PM ET
JPMorgan Initiates Coverage on Definium Therapeutics With Overweight Rating, $84 Price Target
MT Newswires · Oct 9, 2026 7:33 AM ET
Jefferies Highlights Three Biotech Stocks With Blockbuster Potential
Investing.com · Sep 30, 2026 3:32 PM ET
Definium Therapeutics Insider Sold Shares Worth $1,153,784, According to a Recent SEC Filing
MT Newswires · Sep 30, 2026 4:02 AM ET
Definium Therapeutics Announces New Employee Inducement Grants
Business Wire · Sep 28, 2026 4:01 PM ET
Definium Therapeutics Highlights Phase III DT120 Gains in Anxiety and Depression
MarketBeat · Sep 24, 2026 2:02 AM ET
Financial Overview - Income Statement
Quarterly
No financial data available. Click Refresh on the ticker to load latest fundamentals.
See DFTX's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.